D. Boral Capital has initiated coverage on Avita Medical (NASDAQ:RCEL) with a Buy rating and a 12-month price target of $25, highlighting the company’s potential to revolutionize soft tissue and skin care through its cutting-edge Recell technology.
Avita’s flagship platform, Recell, has demonstrated impressive results in clinical trials, addressing a wide range of wound and burn indications. This innovation paves the way for a comprehensive product suite, including PermeaDerm and Cohealyx, designed to cater to both soft and deep tissue care needs. Together, these products position Avita as a leader in the tissue regeneration market.
The firm’s forecast focuses on U.S. market penetration, which is expected to drive significant growth. While regions such as Europe, the UK, Australia, Japan, and China are excluded from the current model, they represent additional opportunities that could further enhance Avita’s potential.